As stakeholders ramp up peptide-synthesis and mRNA manufacturing, the foundation is laid for dual-agonist and fusion therapies that promise enhanced efficacy and safety in diabetes care. With established GLP-1 agonists like tirzepatide and semaglutide leading the way, the next 2–5 years are projected to see broader adoption of these innovative treatments alongside regulatory refinement and reduced costs. Long-term monitoring will be crucial to maintaining confidence as the healthcare landscape evolves with these emerging modalities.
Title not available for this citation.
“Association of oral semaglutide with cardiovascular outcomes in a real-world primary prevention population.”
Title not available for this citation.
“After adjusting for baseline covariates, relative to baseline, participants achieving BMI <25 kg/m2 had a significantly greater percent reduction in predicted ASCVD risk (39.4% vs 10.6%, P < 0.001) compared to the BMI ≥25 kg/m2 group.”
Title not available for this citation.
“Among those with baseline intermediate-to-high ASCVD risk, reduction remained greater in the BMI <25 kg/m2 group (25.6%) than the BMI ≥25 kg/m2 group (9.0%; P < 0.001).”
Title not available for this citation.
“Significantly greater improvements were also observed in blood pressure and lipids for the BMI <25 kg/m2 group (P < 0.001).”
Title not available for this citation.
“Tirzepatide was first approved by the FDA for type 2 diabetes in May 2022 and subsequently for obesity in November 2023.”
Title not available for this citation.
“Tirzepatide... has demonstrated significant efficacy in glycemic control and weight reduction.”
Title not available for this citation.
“its immunomodulatory properties suggest potential therapeutic roles in conditions like psoriasis and hidradenitis suppurativa.”
Title not available for this citation.
“We undertook a four week non-randomized, controlled open-label study examining proteomic changes... in response to GLP-1 agonist, semaglutide (0.25 mg weekly) added to standard of care anticoagulation in patients with intermediate high-risk PE.”
Title not available for this citation.
“The development of scalable and efficient manufacturing of high-volume complex synthetic peptides and proteins, like tirzepatide (TZP, 1), faces major hurdles due to the limitations of traditional Solid Phase Peptide Synthesis (SPPS) and Liquid Phase Peptide Synthesis (LPPS).”
Title not available for this citation.
“To enable the commercial synthesis of tirzepatide, we pioneered an innovative four-fragment convergent hybrid SPPS/LPPS strategy combining their individual strengths.”
Title not available for this citation.
“This NCL/TFF combination offers a powerful, orthogonal, and greener path to TZP, representing a meaningful innovation in synthetic peptide process chemistry.”
Title not available for this citation.
“GLP-1 RA co-exposure was associated with lower mortality (hazard ratio [HR] 0.55, 95 % CI 0.51-0.61; 36-month absolute risk difference [ARD] - 16.41 %; number needed to treat [NNT] 5).”
